To assess the potential of TLCD1 in predicting the efficacy of immune checkpoint inhibitor (ICI) therapy, we evaluated its correlation with two well-established predictive biomarkers for immunotherapy (Chan et al., 2019; Zhao et al., 2019), namely, tumor mutational burden (TMB) and microsatellite instability (MSI) (Figures 6B, C). The gene discussed is TLCD1; the disease is neoplasm.